De-extinction startup Colossal Biosciences, a company that captured global attention last year with its ambitious plan to "resurrect" the dire wolf from fossilized genetic material, is now reportedly in discussions to secure new funding at a valuation ranging from $20 billion to $30 billion. This potential financial milestone, coming roughly 16 months after its last valuation of $10.2 billion, underscores a burgeoning investor confidence not only in the audacious concept of de-extinction but also in the diverse and rapidly evolving deep-tech portfolio Colossal has cultivated. The reported valuation jump highlights a significant re-evaluation of the company’s underlying genetic engineering, synthetic biology, and computational biology technologies, which are finding applications far beyond bringing back extinct species.
A Rapid Ascent in Deep Tech Valuations
The news of the impending funding round, first reported by Axios, places Colossal Biosciences at the forefront of a dynamic deep-tech investment landscape. While the lead investor and the exact capital sought remain undisclosed, the report indicates that the five-year-old company has recently begun generating revenue, a critical turning point for any startup, especially one operating in such a capital-intensive and research-heavy domain. This revenue generation, coupled with a string of strategic spin-offs and partnerships, appears to be the primary driver behind the anticipated doubling or tripling of its valuation in a relatively short period.
Colossal Biosciences, co-founded by tech entrepreneur Ben Lamm and renowned geneticist George Church, initially garnered headlines for its audacious mission to bring back iconic extinct species like the woolly mammoth and the dodo bird. The announcement in early 2025 regarding its intent to de-extinct the dire wolf, a formidable predator that roamed North America until approximately 10,000 years ago, further solidified its position as a pioneer, albeit a controversial one, in the nascent field of de-extinction. Critics often question the ethical implications, ecological feasibility, and the allocation of resources to such projects when countless extant species face extinction. However, proponents, including Colossal itself, argue that the technologies developed for de-extinction have profound implications for modern conservation, human health, and various industrial applications.
Diversifying Beyond De-Extinction: A Strategic Imperative
From its inception, Colossal’s leadership articulated a vision that extended beyond the headline-grabbing de-extinction projects. CEO Ben Lamm had previously outlined three primary revenue streams for the business, a strategy that is now evidently bearing fruit and justifying its escalating valuation. These streams demonstrate a shrewd understanding of how to commercialize cutting-edge biological research and development.
The first revenue stream involves conservation technology. Colossal has actively offered its advanced genetic and reproductive technologies to governmental bodies and international organizations for the preservation of critically endangered species. A notable example is the reported $60 million investment from the United Arab Emirates, as detailed by Wired, indicating a serious commitment from sovereign entities to leverage Colossal’s capabilities. Furthermore, the company has partnered with the U.S. government, specifically the Department of Interior, to explore applications of its gene-editing and reproductive technologies for endangered species. This involves not just de-extinction, but also "genetic rescue" — enhancing the genetic diversity or disease resistance of existing vulnerable populations, a less controversial but equally impactful application of their core science.
The second major pillar of Colossal’s financial strategy lies in the strategic spin-off of specialized startups. These ventures leverage the foundational technologies developed within Colossal but target distinct, high-growth markets.
- Breaking: This spin-off focuses on developing biotechnological solutions for breaking down plastics. Leveraging synthetic biology and enzyme engineering, Breaking aims to address the global plastic waste crisis, a market with immense environmental urgency and economic potential. The ability to bio-engineer organisms or enzymes to degrade complex polymers represents a significant advancement in sustainable technology.
- Form Bio: A computational biology platform, Form Bio secured a substantial $30 million in funding. This company provides the crucial software and analytical infrastructure that underpins modern biological research, including genomics, proteomics, and drug discovery. In an era where biological data is exploding, platforms that can efficiently process, analyze, and model complex biological systems are indispensable, making Form Bio a valuable asset in the biotech ecosystem.
- Astromech: Perhaps the most financially significant spin-off to date, Astromech is an AI-driven predictive modeling company specializing in biology and life sciences. Valued at an impressive $2 billion in March, Astromech’s focus on artificial intelligence to accelerate discovery and development in areas like drug design, gene therapy, and diagnostics highlights the immense value placed on the intersection of AI and biotech. Its high valuation independently validates the technological prowess originating from Colossal’s core research.
These spin-offs collectively demonstrate that Colossal is not merely a de-extinction company; it is a synthetic biology and genetic engineering powerhouse capable of generating diverse commercial applications. The success of these subsidiaries directly contributes to the parent company’s overall valuation, showcasing a robust strategy for monetizing its intellectual property and scientific breakthroughs.
Expanding the De-Extinction Portfolio and Conservation Efforts
While the spin-offs diversify revenue, Colossal has simultaneously continued to expand its direct de-extinction and conservation initiatives. Operating from its expansive 55,000-square-foot headquarters in Dallas, the company has consistently added new target species to its de-extinction portfolio. In late April, the bluebuck antelope was announced as its sixth target species. The bluebuck, native to South Africa, was hunted to extinction in the early 19th century, making its potential revival a significant conservation endeavor for African ecosystems.
Beyond de-extinction, Colossal has also demonstrated its commitment to the broader field of conservation through its nonprofit arm, the Colossal Foundation. Late last month, the Foundation announced a partnership with the University of Tasmania. This collaboration aims to combat the devastating Devil Facial Tumour Disease (DFTD), a contagious cancer threatening the survival of the iconic Tasmanian devil. The initiative plans to utilize cutting-edge genetic tools, including gene editing and vaccine development, to help protect the remaining wild populations. This project exemplifies how Colossal’s core technologies, originally envisioned for de-extinction, can be directly applied to "genetic rescue" and disease resistance in critically endangered living species, offering a tangible and immediate conservation benefit.
Future Horizons: Artificial Wombs and Biodiversity Credits
Looking further into the future, Colossal Biosciences is exploring additional highly innovative and potentially lucrative ventures. CEO Ben Lamm revealed plans to spin off the company’s artificial animal womb technology. This technology, developed to gestate de-extinct species, holds immense potential for applications in human fertility treatment. In an interview with Rolling Stone in May, Lamm projected that this groundbreaking technology could be ready for human application as early as next year. The prospect of artificial wombs has profound implications for addressing infertility, supporting high-risk pregnancies, and potentially redefining human reproduction, though it is also an area ripe for intense ethical and societal debate. The market for fertility treatments globally is substantial and growing, representing another significant potential revenue stream.
Moreover, Lamm has articulated a long-term vision for generating revenue through the sale of biodiversity credits. This market-based mechanism, analogous to carbon credits, would allow companies or individuals to invest in projects that demonstrably enhance biodiversity. If Colossal successfully reintroduces extinct animals like the woolly mammoth into their native habitats, particularly in the Arctic tundra where mammoths could help restore grasslands and mitigate permafrost melt, these ecological restoration efforts could theoretically generate measurable biodiversity uplift. This would create a new asset class where the ecological services provided by revived species could be monetized, aligning conservation goals with economic incentives. The nascent biodiversity credit market is still developing but is poised for significant growth as environmental, social, and governance (ESG) investing gains traction globally.
The Broader Deep Tech Boom and Market Dynamics
Colossal Biosciences’ soaring valuation is not an isolated phenomenon but rather emblematic of a broader boom in deep-tech sectors. Investors are increasingly pouring capital into areas such as longevity tech, alternative energy, quantum computing, and advanced biotechnology. These sectors are characterized by highly complex scientific foundations, long development cycles, significant capital requirements, but also the potential for transformative impact and massive returns on investment. The global biotech market alone is projected to reach over a trillion dollars in the coming years, driven by innovations in gene therapy, personalized medicine, and synthetic biology.
The market for gene editing, a core capability of Colossal, is also experiencing rapid expansion. Technologies like CRISPR, fundamental to Colossal’s work, are revolutionizing everything from agriculture to human disease treatment. The synthetic biology market, encompassing the design and construction of new biological parts, devices, and systems, is also on an upward trajectory, estimated to grow at a compound annual growth rate of over 25%. Colossal’s ability to demonstrate tangible progress in these areas, coupled with its strategic diversification into adjacent high-value markets, has clearly resonated with investors.
Despite the excitement, the deep-tech landscape also carries inherent risks. The scientific challenges are immense, regulatory hurdles can be significant, and public acceptance of radical technologies like de-extinction or artificial wombs is not guaranteed. However, the reported valuation indicates that investors are betting heavily on Colossal’s scientific leadership, strategic foresight, and its capacity to deliver on its ambitious promises while simultaneously spinning off profitable ventures.
Colossal Biosciences did not respond to requests for comment regarding the reported fundraising discussions. As the company continues its groundbreaking work from its Dallas headquarters, the biotech world watches closely to see if it can indeed bring back the giants of the past and, in doing so, redefine the future of technology, conservation, and even humanity itself. The journey of Colossal Biosciences serves as a potent illustration of the high stakes, high rewards, and profound ethical considerations that characterize the bleeding edge of scientific innovation in the 21st century.
